ELAN Q4 2020 Earnings — Elanco Animal Health Incorporated Revenue & Financial Results | Market Cap Arena

ELANElanco Animal Health Incorporated

$12B

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.1B+44.8% YoY

Gross Profit

$380M33.3% margin

Operating Income

-$107M-9.4% margin

Net Income

-$323M-28.3% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+28.1%

Cash Flow

Operating Cash Flow

-$93M

Free Cash Flow

-$240M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$17.7B

Total Liabilities

$9.2B

Stockholders' Equity

$8.5B

Cash & Equivalents

$495M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.1B	$787M	+44.8%
Gross Profit	$380M	$326M	+16.7%
Operating Income	-$107M	$72M	-248.0%
Net Income	-$323M	-$10M	-3297.9%

Revenue Segments

Farm Animal Ruminants And Swine

$808M34%

Pet Health Disease Prevention

$696M29%

Farm Animal Future Protein And Health

$553M23%

Pet Health Therapeutics

$263M11%

Contract Manufacturing

$64M3%

Geographic Segments

Non-US

$634M56%

UNITED STATES

$506M44%